PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34347777-0 2021 Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 34347777-13 2021 Furthermore, we demonstrated direct inhibition of paclitaxel-induced ABCB1 transporter activity by both lapatinib and poziotinib. Lapatinib 104-113 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 34347777-14 2021 In conclusion, lapatinib and poziotinib combined with paclitaxel synergizes to inhibit the proliferation of ABCB1-overexpressing ovarian cancer cells in vitro. Lapatinib 15-24 ATP binding cassette subfamily B member 1 Homo sapiens 108-113 31177402-0 2020 The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. Lapatinib 107-116 ATP binding cassette subfamily B member 1 Homo sapiens 45-59 35463361-0 2022 Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1- Mediated Gemcitabine Chemoresistance. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 73-78 35463361-5 2022 The synergistic effect of lapatinib and gemcitabine was interpreted by docking analysis, ABCB1-associated ATPase assay, rhodamine transport assay and LC-MS/MS analyses. Lapatinib 26-35 ATP binding cassette subfamily B member 1 Homo sapiens 89-94 35463361-8 2022 Lapatinib exerts a dual effect on HER2-overexpressed CCA, suppressing the growth of CCA cells by inhibiting HER2 and HER2-dependent downstream signaling pathways while inhibiting ABCB1 transporter function, allowing for the accumulation of active gemcitabine metabolites within cells. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 179-184 35463361-9 2022 Conclusions: Our data demonstrates that lapatinib can not only inhibit growth of CCA overexpressing HER2, but can also circumvent ABCB1-mediated chemoresistance after gemcitabine treatment. Lapatinib 40-49 ATP binding cassette subfamily B member 1 Homo sapiens 130-135 33147005-0 2020 Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization. Lapatinib 135-144 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 31177402-3 2020 The aim of this study was to investigate the effects of elacridar, an ABCB1 and ABCG2 inhibitor, on the brain and cerebrospinal fluid uptake of lapatinib. Lapatinib 144-153 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 31177402-9 2020 The inhibition of ABCB1 and ABCG2 transporters by elacridar substantially enhanced the penetration of lapatinib into the CSF and BT. Lapatinib 102-111 ATP binding cassette subfamily B member 1 Homo sapiens 18-23 28596528-0 2017 Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 84-89 31262905-6 2019 In a detailed quantitative analysis using lower doses, we demonstrated that lapatinib, with high P-gp inhibitory activity, yielded the best pairing for sensitizing P-gp-overexpressing KBV20C cells to vincristine. Lapatinib 76-85 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 31262905-6 2019 In a detailed quantitative analysis using lower doses, we demonstrated that lapatinib, with high P-gp inhibitory activity, yielded the best pairing for sensitizing P-gp-overexpressing KBV20C cells to vincristine. Lapatinib 76-85 ATP binding cassette subfamily B member 1 Homo sapiens 164-168 31262905-8 2019 Lapatinib was shown to have a higher P-gp-inhibitory activity than verapamil, even at lower doses, indicating that its sensitizing of cells to vincristine involves its P-gp-inhibitory effects. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 31262905-8 2019 Lapatinib was shown to have a higher P-gp-inhibitory activity than verapamil, even at lower doses, indicating that its sensitizing of cells to vincristine involves its P-gp-inhibitory effects. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 28596528-5 2017 Mechanistically, the synergy was based on a lapatinib induced inhibition of the multidrug-resistance efflux transporter ABCB1, which is frequently expressed in resistant neuroblastoma cells, which allowed prolonged and elevated cytotoxicity of YM155. Lapatinib 44-53 ATP binding cassette subfamily B member 1 Homo sapiens 120-125 26036634-5 2015 Lapatinib was shown to increase the accumulation of doxorubicin in ABCB1-overexpressing hepatocellular cancer cells and normal liver tissues without altering the protein level of ABCB1. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 67-72 27137717-1 2015 The potential for an interaction between lapatinib and absorption of the P-glycoprotein (ABCB1) substrate digoxin at a therapeutic dose in breast cancer patients was characterized. Lapatinib 41-50 ATP binding cassette subfamily B member 1 Homo sapiens 89-94 27137717-5 2015 Lapatinib 1500 mg/day increased digoxin absorption approximately 80%, implicating lapatinib inhibition of intestinal ABCB1-mediated efflux. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 27137717-5 2015 Lapatinib 1500 mg/day increased digoxin absorption approximately 80%, implicating lapatinib inhibition of intestinal ABCB1-mediated efflux. Lapatinib 82-91 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 27137717-6 2015 In summary, coadministration of lapatinib with narrow therapeutic index drugs that are substrates of ABCB1 should be undertaken with caution and dose adjustment should be considered. Lapatinib 32-41 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 26036634-8 2015 Our study thus revealed for the first time that the higher incidence of hepatotoxicity during this combinational treatment was due to the increased drug accumulation in hepatocytes mediated by the inhibition of ABCB1 by lapatinib. Lapatinib 220-229 ATP binding cassette subfamily B member 1 Homo sapiens 211-216 26054673-5 2015 The results showed that inhibition of EGFR/HER2 signaling by lapatinib sensitized MCF-7 tumorspheres to doxorubicin by inhibiting the expression of the ABC transporters, MDR-1 and BCRP, and thus, enhancing the intracellular accumulation of doxorubicin. Lapatinib 61-70 ATP binding cassette subfamily B member 1 Homo sapiens 170-175 19854117-11 2009 Additionally, over-expression of the membrane protein drug transporter, P-glycoprotein (P-gp) a common cancer drug resistance mechanism, greatly reduces the cellular accumulation of dasatinib but not of lapatinib. Lapatinib 203-212 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 22414725-2 2012 Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2). Lapatinib 29-38 ATP binding cassette subfamily B member 1 Homo sapiens 220-244 22414725-2 2012 Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2). Lapatinib 29-38 ATP binding cassette subfamily B member 1 Homo sapiens 246-251 22414725-2 2012 Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2). Lapatinib 40-48 ATP binding cassette subfamily B member 1 Homo sapiens 220-244 22414725-2 2012 Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2). Lapatinib 40-48 ATP binding cassette subfamily B member 1 Homo sapiens 246-251 22414725-3 2012 In the present study, we conducted in vitro experiments to evaluate if GW583340 and GW2974, structural analogues of lapatinib, could reverse ABCB1- and ABCG2-mediated MDR. Lapatinib 116-125 ATP binding cassette subfamily B member 1 Homo sapiens 141-146 22389470-7 2012 Moreover, knocking down of HER2 by an short interfering RNA weakened the effect of lapatinib on ABCB1, indicating the involvement of HER2 in the inhibitory mechanisms. Lapatinib 83-92 ATP binding cassette subfamily B member 1 Homo sapiens 96-101 19720054-3 2010 Previously, we showed that lapatinib and erlotinib could inhibit the drug efflux function of P-glycoprotein (P-gp, ABCB1) and ABCG2 transporters. Lapatinib 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 93-107 19720054-3 2010 Previously, we showed that lapatinib and erlotinib could inhibit the drug efflux function of P-glycoprotein (P-gp, ABCB1) and ABCG2 transporters. Lapatinib 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 19720054-3 2010 Previously, we showed that lapatinib and erlotinib could inhibit the drug efflux function of P-glycoprotein (P-gp, ABCB1) and ABCG2 transporters. Lapatinib 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 115-120 25105301-2 2014 Lapatinib can modulate the function of ATP-binding cassette (ABC) transporters (ABCB1 and ABCG2), which are the major mechanism responsible for multidrug resistance (MDR) in cancer. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 80-85 20607587-0 2011 Modulation of P-gp expression by lapatinib. Lapatinib 33-42 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 20607587-4 2011 We examined the impact of co-incubation of chemotherapy drugs in combination with lapatinib in P-gp over-expressing drug resistant cells. Lapatinib 82-91 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 20607587-5 2011 Unexpectedly, lapatinib treatment, at clinically relevant concentrations, increased levels of the P-gp drug transporter in a dose- and time-responsive manner. Lapatinib 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 20607587-7 2011 Despite the lapatinib-induced alteration in P-gp expression, use of accumulation, efflux and toxicity assays demonstrated that the induced alteration in P-gp expression by lapatinib had little direct impact on drug resistance. Lapatinib 12-21 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 20607587-7 2011 Despite the lapatinib-induced alteration in P-gp expression, use of accumulation, efflux and toxicity assays demonstrated that the induced alteration in P-gp expression by lapatinib had little direct impact on drug resistance. Lapatinib 172-181 ATP binding cassette subfamily B member 1 Homo sapiens 153-157 21514634-3 2011 We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan. Lapatinib 117-126 ATP binding cassette subfamily B member 1 Homo sapiens 184-187 21514634-15 2011 Disruption of erbB signaling and BCRP/Pgp efflux with lapatinib was insufficient for overcoming topotecan resistance, suggesting alternative mechanisms of resistance are involved. Lapatinib 54-63 ATP binding cassette subfamily B member 1 Homo sapiens 38-41 19854117-11 2009 Additionally, over-expression of the membrane protein drug transporter, P-glycoprotein (P-gp) a common cancer drug resistance mechanism, greatly reduces the cellular accumulation of dasatinib but not of lapatinib. Lapatinib 203-212 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 18829547-0 2008 Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 105-161 18829547-0 2008 Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Lapatinib 11-17 ATP binding cassette subfamily B member 1 Homo sapiens 105-161 18829547-0 2008 Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Lapatinib 19-27 ATP binding cassette subfamily B member 1 Homo sapiens 105-161 18829547-3 2008 The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters. Lapatinib 56-65 ATP binding cassette subfamily B member 1 Homo sapiens 135-159 18829547-3 2008 The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters. Lapatinib 56-65 ATP binding cassette subfamily B member 1 Homo sapiens 161-166 18829547-4 2008 Our results showed that lapatinib significantly enhanced the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was observed in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells. Lapatinib 24-33 ATP binding cassette subfamily B member 1 Homo sapiens 76-81 18829547-6 2008 Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E(2)17betaG by ABCG2. Lapatinib 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 18829547-7 2008 Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [(125)I]iodoarylazidoprazosin in a concentration-dependent manner. Lapatinib 13-22 ATP binding cassette subfamily B member 1 Homo sapiens 62-67 18829547-7 2008 Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [(125)I]iodoarylazidoprazosin in a concentration-dependent manner. Lapatinib 13-22 ATP binding cassette subfamily B member 1 Homo sapiens 113-118 18829547-9 2008 Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice. Lapatinib 13-22 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 18829547-10 2008 Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function. Lapatinib 26-35 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 18216274-5 2008 Lapatinib is a substrate for the efflux transporters P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP). Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 53-67 18216274-5 2008 Lapatinib is a substrate for the efflux transporters P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP). Lapatinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 69-72 18216274-6 2008 Furthermore, lapatinib is an inhibitor (IC(50) values 0.025-5 muM) of Pgp, BCRP, and organic anion transporting polypeptide 1B1 (a hepatic uptake transporter). Lapatinib 13-22 ATP binding cassette subfamily B member 1 Homo sapiens 70-73 18216274-9 2008 In contrast, systemic exposure of lapatinib after oral dosing was unchanged when efflux by Pgp and BCRP was absent from the gastrointestinal tract. Lapatinib 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 91-94